Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GRITSTONE BIO, INC.

(GRTS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone bio : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5% After-Hours

09/16/2021 | 04:32pm EDT


ę MT Newswires 2021
All news about GRITSTONE BIO, INC.
09/29GRITSTONE BIO, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
09/24Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
09/23ASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
RE
09/20GRITSTONE BIO : Oncology Doses First Volunteer in Phase 1 Trial of COVID-19 Vaccine Booste..
MT
09/20GRITSTONE BIO : Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mR..
AQ
09/20Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA ..
CI
09/20GRITSTONE BIO, INC.(NASDAQGS : GRTS) added to S&P Global BMI Index
CI
09/17GRITSTONE BIO : SECURITIES PURCHASE AGREEMENT (Form 8-K)
PU
09/17GRITSTONE BIO, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
09/17AFTER HOURS WATCH LIST SCORECARD : Abcl, fang, grts
MT
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 47,0 M - -
Net income 2021 -72,9 M - -
Net cash 2021 137 M - -
P/E ratio 2021 -7,92x
Yield 2021 -
Capitalization 590 M 590 M -
EV / Sales 2021 9,66x
EV / Sales 2022 17,1x
Nbr of Employees 181
Free-Float 96,2%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | GRTS | US39868T1051 | MarketScreener
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 9,19 $
Average target price 20,33 $
Spread / Average Target 121%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
RaphaŰl Rousseau Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.133.25%590
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.16.50%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336